Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET scan could slash radiation by 100x

NCT ID NCT07542158

Diagnosis Sponsor: Akiva Mintz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new PET imaging technique that uses 10 to 100 times less radiation than standard scans. Researchers will inject 200 healthy volunteers and patients with a radioactive tracer and use a high-sensitivity scanner to see if image quality remains good enough for detecting Parkinsonian syndromes, neuroendocrine tumors, and gliomas. The goal is to make scans safer without losing diagnostic accuracy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-FDOPA (a radioactive tracer)
What this could lead to
If successful, this could make PET scans safer by drastically reducing radiation exposure while maintaining image quality.
What could go wrong
This is an early-phase imaging study focused on technical improvements, not a treatment. It may not lead to changes in patient care or diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. age ≥18 years. 2. ability to provide informed consent and comply with study procedures. 3. for female participants: * must not be pregnant or breastfeeding. * negative pregnancy test required for women of childbearing potential. Exclusion criteria: 1. participants who have exceeded Nuclear Regulatory Commission regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total). 2. more than four prior enrollments in this study. 3. participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the pet scan 4. medication \& prior treatment exclusions • concurrent treatments that may interfere with radiotracer uptake as determined by the Principal Investigator. 5. pregnant or breastfeeding individuals (negative pregnancy test required) 6. inability to provide informed consent 7. any condition that, in the investigator's judgment, may compromise participant safety or study integrity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gliomas are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioma neoplasm neuroendocrine neoplasm parkinsonian disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gliomas Heathy volunteer Neuroendocrine (NE) tumors Parkinsonian syndromes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nuclear Imaging Institute

    Englewood, New Jersey, 07631, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.